#USA #New York #Class Action #Pomerantz LLP #BioAge Labs

Pomerantz Law Firm Initiates Class Action Against BioAge Labs

In a significant move for investors affected by the recent decline in BioAge Labs, Inc.'s stock price, the Pomerantz Law Firm has announced a class action lawsuit against the company. This lawsuit is particularly important for shareholders who have experienced losses related to their investments in BioAge, which is traded on NASDAQ under the ticker BIOA.

Background of the Case

The class action revolves around allegations that BioAge and certain members of its management and board may have engaged in securities fraud or other unlawful business practices. Since the initial public offering (IPO) on September 26, 2024, where shares were priced at $18.00, BioAge has faced scrutiny following adverse announcements regarding its clinical trials.

On December 6, 2024, the company announced the discontinuation of its STRIDES Phase 2 study for its investigational drug azelaprag due to liver transaminitis observed in participants. This critical news led to a drastic drop in stock value, with shares plummeting by over 76%, closing at just $4.65 on December 9, 2024. Such a severe drop has raised serious concerns among investors about the company's compliance with securities regulations and corporate governance standards.

What Investors Need to Know

Investors who acquired BioAge securities during the class period are advised to act promptly. Those interested in becoming a Lead Plaintiff in the class action must take legal action by March 10, 2025. Pomerantz recommends contacting their office at [email protected] or by phone at 646-581-9980 (toll-free: 888.4-POMLAW, Ext. 7980). When reaching out, investors should provide their basic contact details and the number of shares acquired.

This class action lawsuit stems from broader issues regarding transparency and ethical conduct in publicly traded companies. It is a reminder for stakeholders to remain vigilant and informed about their investments, especially in sectors that precede significant medical developments.

About Pomerantz Law Firm

Pomerantz LLP is recognized as a leading firm specializing in corporate, securities, and antitrust class litigation. Established over 85 years ago by Abraham L. Pomerantz, known as a pioneer in securities class actions, the firm has successfully recovered significant settlements for victims of corporate misconduct. With offices in key global cities including New York, Chicago, and London, Pomerantz is committed to protecting investors' rights and promoting accountability among corporations.

For more detailed information and future updates regarding this lawsuit and its proceedings, affected investors are encouraged to visit the official website at www.pomerantzlaw.com.

Conclusion

This development presents an opportunity for affected investors to reclaim losses through collective legal action. As concerns about corporate governance and ethical compliance grow, the outcome of this class action against BioAge Labs could set important precedents for investor protection within the biotechnology sector.